Xilio Therapeutics, INC. (XLO) — SEC Filings

Overview

Xilio Therapeutics, INC. (XLO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 3 filed on Apr 16, 2026: On April 15, 2026, Xilio Therapeutics, Inc. filed an initial statement of beneficial ownership of securities (Form 3). The filing was made by Cheryl R. Blanchard, who is listed as the reporting person. The company's mailing address is 828 Winter Street, Waltham, MA 02451.

Sentiment Summary

Across 45 filings, the sentiment breakdown is: 7 bearish, 37 neutral, 1 mixed. The dominant filing sentiment for Xilio Therapeutics, INC. is neutral.

Filing Type Overview

Xilio Therapeutics, INC. (XLO) has filed 1 3, 1 4, 21 8-K, 6 10-Q, 3 DEF 14A, 2 10-K, 8 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (45)

• 4 Filing — 4 · Apr 16, 2026
• Xilio Therapeutics Files Initial Ownership Statement — 3 · Apr 16, 2026 Risk: low
  On April 15, 2026, Xilio Therapeutics, Inc. filed an initial statement of beneficial ownership of securities (Form 3). The filing was made by Cheryl R. Blanchar
• Xilio Therapeutics Files 8-K on Officer Changes — 8-K · Apr 16, 2026 Risk: low
  On April 16, 2026, Xilio Therapeutics, Inc. filed an 8-K report detailing changes in its executive officers and compensatory arrangements. The filing specifical
• 8-K Filing — 8-K · Nov 25, 2025
• Xilio's Revenue Surges, But Warrant Liabilities Deepen Net Loss — 10-Q · Nov 13, 2025 Risk: high
  Xilio Therapeutics, Inc. reported a significant increase in collaboration and license revenue to $19.066 million for the three months ended September 30, 2025,
• Xilio Therapeutics Files 8-K — 8-K · Nov 7, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on November 7, 2025, reporting on Item 8.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits).
• Xilio Seeks Shareholder Nod for Option Repricing, New Stock Plan — DEF 14A · Oct 20, 2025 Risk: medium
  Xilio Therapeutics, Inc. (XLO) is holding a special meeting on November 21, 2025, to seek stockholder approval for two critical compensation-related proposals:
• Xilio Therapeutics Faces Delisting Notice — 8-K · Oct 3, 2025 Risk: high
  Xilio Therapeutics, Inc. filed an 8-K on October 3, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company's principa
• Xilio Therapeutics Files 8-K Report — 8-K · Sep 9, 2025 Risk: low
  On September 9, 2025, Xilio Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indica
• Xilio Therapeutics Faces Delisting Concerns — 8-K · Aug 28, 2025 Risk: high
  Xilio Therapeutics, Inc. filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earlie
• Xilio's Losses Mount Amid R&D Spend, Cash Position Boosted by Offering — 10-Q · Aug 14, 2025 Risk: high
  Xilio Therapeutics, Inc. reported a net loss of $15.844 million for the three months ended June 30, 2025, an increase from $13.925 million in the same period of
• Xilio Therapeutics Files 8-K on Shareholder Vote — 8-K · Jun 12, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on June 12, 2025, reporting on matters submitted to a vote of security holders on June 10, 2025. The filing details the co
• Xilio Therapeutics Board Changes: New Directors Elected, Two Depart — 8-K · Jun 10, 2025 Risk: medium
  On June 10, 2025, Xilio Therapeutics, Inc. filed an 8-K report detailing the departure of two directors, Dr. Jeffrey W. Allen and Dr. Steven M. Altschuler, effe
• Xilio Therapeutics Files 8-K: Material Agreement, Other Events — 8-K · Jun 3, 2025 Risk: medium
  On June 2, 2025, Xilio Therapeutics, Inc. entered into a material definitive agreement. The company also made a Regulation FD disclosure and reported other even
• Xilio Therapeutics Files 8-K — 8-K · Jun 2, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on June 2, 2025, reporting events as of May 31, 2025. The filing primarily concerns financial statements and exhibits, alo
• Xilio Therapeutics Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  Xilio Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's primary focus remains on its clinical-stage immuno-oncology programs
• Xilio Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 28, 2025 Risk: low
  Xilio Therapeutics, Inc. filed its definitive proxy statement on April 28, 2025, for its annual meeting on June 10, 2025. The company, incorporated in Delaware
• Xilio Therapeutics to be Delisted from Nasdaq — 8-K · Apr 8, 2025 Risk: high
  Xilio Therapeutics, Inc. announced on April 4, 2025, that it received a notice from the Nasdaq Stock Market indicating non-compliance with listing rules. The co
• Xilio Therapeutics Files 8-K on Financials — 8-K · Mar 11, 2025 Risk: low
  On March 11, 2025, Xilio Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as w
• Xilio Therapeutics Files 2024 10-K — 10-K · Mar 11, 2025 Risk: medium
  Xilio Therapeutics, Inc. filed its 2024 10-K on March 11, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company, b
• Xilio Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Feb 12, 2025 Risk: medium
  On February 10, 2025, Xilio Therapeutics, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securitie
• Xilio Therapeutics Files 8-K — 8-K · Jan 21, 2025 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting on other events and financial statements. The filing does not contain specific financial fi
• Xilio Therapeutics Raises $15M in Private Placement — 8-K · Dec 19, 2024 Risk: medium
  On December 18, 2024, Xilio Therapeutics, Inc. announced the closing of its previously disclosed private placement of common stock. The company raised approxima
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Xilio Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  Xilio Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial condition and business operations, inclu
• SC 13G Filing — SC 13G · Sep 27, 2024
• Xilio Therapeutics Faces Nasdaq Delisting Warning — 8-K · Sep 13, 2024 Risk: high
  Xilio Therapeutics, Inc. announced on September 10, 2024, that it received a notification from The Nasdaq Stock Market LLC regarding its failure to meet the min
• Xilio Therapeutics Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Xilio Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business act
• SC 13G/A Filing — SC 13G/A · Jul 31, 2024
• Xilio Therapeutics Files 8-K on Shareholder Matters — 8-K · Jun 17, 2024 Risk: low
  Xilio Therapeutics, Inc. filed an 8-K on June 17, 2024, reporting on matters submitted to a vote of security holders as of June 13, 2024. The filing details the
• Xilio Therapeutics Announces Board and Executive Changes — 8-K · Jun 13, 2024 Risk: medium
  On June 13, 2024, Xilio Therapeutics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. Specifically, the company
• Xilio Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: medium
  Xilio Therapeutics, Inc. (XLO) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Xilio Therapeutics, Inc. filed a 10-Q for the period ending March 3
• Xilio Therapeutics Announces 2024 Annual Meeting of Stockholders on June 13 — DEF 14A · Apr 25, 2024 Risk: low
  Xilio Therapeutics, Inc. (XLO) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. Xilio Therapeutics will hold its 2024 Annual Meeting of Stockho
• SC 13G Filing — SC 13G · Apr 5, 2024
• SC 13G/A Filing — SC 13G/A · Apr 5, 2024
• Xilio Therapeutics, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Apr 1, 2024 Risk: medium
  Xilio Therapeutics, Inc. (XLO) filed a Annual Report (10-K) with the SEC on April 1, 2024. Xilio Therapeutics, Inc. filed its annual report on Form 10-K for the
• Xilio Therapeutics Files 8-K: Material Agreement, Financials, and More — 8-K · Mar 28, 2024 Risk: medium
  On March 27, 2024, Xilio Therapeutics, Inc. entered into a Material Definitive Agreement, the details of which are not fully disclosed in this filing. The compa
• SC 13G Filing — SC 13G · Feb 14, 2024
• Octagon Capital Advisors Exits Xilio Therapeutics Stake — SC 13G/A · Feb 6, 2024
  Octagon Capital Advisors LP, a Delaware-based investment firm, filed an Amendment No. 2 to its Schedule 13G on February 6, 2024, indicating a significant change
• Octagon Capital Advisors LP Holds 1.785M Shares of Xilio Therapeutics — SC 13G/A · Feb 5, 2024
  Octagon Capital Advisors LP, a Delaware-based investment firm, filed an amended Schedule 13G/A on February 5, 2024, disclosing its beneficial ownership in Xilio
• Xilio Therapeutics to be Delisted from Nasdaq Global Select Market — 8-K · Jan 19, 2024
  Xilio Therapeutics, Inc. (XLO) announced on January 19, 2024, that it received a notice from Nasdaq indicating its common stock will be delisted from the Nasdaq
• Xilio Therapeutics Reports Officer/Director Changes, Comp Arrangements — 8-K · Jan 3, 2024
  Xilio Therapeutics, Inc. filed an 8-K on January 3, 2024, reporting an event that occurred on January 1, 2024, related to the departure or election of directors

Related Companies

ABBV · GILD · RHHBY

Frequently Asked Questions